Alnylam Pharmaceuticals Files 8-K
Ticker: ALNY · Form: 8-K · Filed: Dec 11, 2025 · CIK: 1178670
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory-update
Related Tickers: ALNY
TL;DR
ALNY filed an 8-K on 12/10/25 for other events and exhibits.
AI Summary
On December 10, 2025, Alnylam Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and business operations. No specific new material events or financial figures were detailed in the provided excerpt.
Why It Matters
This 8-K filing signals that Alnylam Pharmaceuticals is providing updated information to the SEC, which could include material business developments or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report without immediate disclosure of significant negative events or financial distress.
Key Players & Entities
- Alnylam Pharmaceuticals, Inc. (company) — Registrant
- December 10, 2025 (date) — Date of earliest event reported
- 675 West Kendall Street (location) — Principal executive offices address
- Cambridge, MA (location) — Principal executive offices city and state
- 02142 (location) — Principal executive offices zip code
FAQ
What is the primary purpose of this 8-K filing by Alnylam Pharmaceuticals?
The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily concerning 'Other Events' and 'Financial Statements and Exhibits'.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported was on December 10, 2025.
What is Alnylam Pharmaceuticals' principal executive office address?
The address is 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142.
What is Alnylam Pharmaceuticals' telephone number?
The registrant's telephone number is (617) 551-8200.
What is Alnylam Pharmaceuticals' IRS Employer Identification No.?
The IRS Employer Identification No. is 77-0602661.
Filing Stats: 1,059 words · 4 min read · ~4 pages · Grade level 15.3 · Accepted 2025-12-11 07:25:04
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share ALNY The Nasdaq
- $34.4 million — cash (the "Repurchases") approximately $34.4 million aggregate principal amount of the Notes
- $51.9 million — d and unpaid interest) of approximately $51.9 million. The final aggregate cash repurchase pr
- $362.8 million — Following such closings, approximately $362.8 million aggregate principal amount of the Notes
Filing Documents
- d201569d8k.htm (8-K) — 28KB
- d201569dex991.htm (EX-99.1) — 10KB
- g201569dsp005.jpg (GRAPHIC) — 6KB
- 0001193125-25-315047.txt ( ) — 162KB
- alny-20251210.xsd (EX-101.SCH) — 2KB
- alny-20251210_lab.xml (EX-101.LAB) — 18KB
- alny-20251210_pre.xml (EX-101.PRE) — 11KB
- d201569d8k_htm.xml (XML) — 4KB
Forward-looking Statements
Forward-looking Statements Various statements in this Current Report on Form 8-K concerning the Company's future expectations, plans and prospects, including, without limitation, statements regarding: the Repurchases, the amount of Notes that will remain outstanding after the Repurchases and the capped call transactions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to the Company's ability to successfully execute on its "Alnylam P5x25" strategy; the Company's ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for the Company's product candidates; or advice of regulatory agencies and the Company's ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling the Company's approved products globally; delays, interruptions or failures in the manufacture and supply of its product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; the Company's ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future; the Company's ability to maintain strategic business collaborations; the Company's dependence on third parties for the development and commercialization of certain products; the outcome of litigation; the potential risk of future government investigations; and unexpected expenditures; as well as those risks more fully
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 11, 2025 ALNYLAM PHARMACEUTICALS, INC. By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chief Financial Officer